Laurus Labs Q2 result: Net profit soars nearly 10-fold YoY to ₹195 crore; interim dividend declared

The pharmaceutical company posted a nearly 10-fold year-on-year (YoY) surge in its consolidated net profit attributable to owners of the company to ₹194.97 crore during the quarter under review.

During the corresponding period of the 2024-25 fiscal year (Q2FY25), its profit stood at ₹19.84 crore, it said in a regulatory filing.

Its revenue from operations witnessed 35% YoY growth at ₹1,653 crore in the September quarter of FY26, compared to ₹1,224 crore in Q2FY25. It was primarily bolstered by robust CDMO (Contract Development and Manufacturing Organization) performance, which was supported by generics growth (both FDF and API business).

During the quarter, the drugmaker’s generics segment contributed 69% to the revenue mix, down 4% over the previous year, with the generic API and FDF businesses making up 37% and 32%, respectively.

Meanwhile, the CDMO business made up 31%, with the contribution increasing by 4% YoY. The CDMO small molecules stood at 28% of the revenue mix, and CDMO bio made up 3%.

At an operational level, its EBITDA (earnings before interest, tax, depreciation and amortisation), also known as operating profit, advanced 136% YoY to ₹429 crore in the September quarter of FY26, as against ₹182 crore in Q2FY25.

Its EBITDA margin expanded to 26% in Q2FY26, compared to 14.9% in the September quarter of the previous fiscal year.

Board declares interim dividend

The Board of Directors of Laurus Labs also approved an interim dividend of ₹0.80 per equity share with a face value of ₹2 each for FY26.

The company fixed October 31, 2025, as the record date for determining the eligibility of the shareholders. The dividend amount will be paid on or after November 12, 2025.

What the CEO said

Commenting on the earnings, Satyanarayana Chava, Founder & Chief Executive Officer of Lauras Lab, said: “We continue to maintain a leadership position in ARVs and make encouraging progress in delivering important clinical and commercial programs. Our Q2 reflects the ongoing expansion of the CDMO business, supported by sustained growth in Generics.”

“Earlier this quarter, we announced land allocation from the Andhra government and proposed investments to support future business expansion, augmenting our offerings across manufacturing scale and new technologies. We also made a strategic investment of “$2 million in Aarvik Therapeutics to have access to novel Antibody-drug conjugates (ADC) technology and pipeline aimed at accelerating our integrated ADC services. I have increasing confidence that our R&D driven commercial strategy will continue to generate long-term value for our stakeholders,” he added.

Shares of Laurus Labs closed 2.07% higher at ₹943 apiece on the National Stock Exchange (NSE) on Thursday. However, the results were declared right as the market closed.

The pharmaceutical has a total market capitalisation of ₹50,905.49 crore, as of October 23, 2025, according to data on the NSE.